International, Multicenter, Open-label, Phase II Study to Investigate the Efficacy and Safety of Multiple Doses of IMAB362 in Patients With Advanced Adenocarcinoma of the Stomach or the Lower Esophagus.

Trial Profile

International, Multicenter, Open-label, Phase II Study to Investigate the Efficacy and Safety of Multiple Doses of IMAB362 in Patients With Advanced Adenocarcinoma of the Stomach or the Lower Esophagus.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Claudiximab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors Ganymed Pharmaceuticals
  • Most Recent Events

    • 17 Dec 2015 Status changed from active, no longer recruiting to completed.
    • 08 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov
    • 27 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top